Vestibular schwannoma is a rare tumor, which is easily misdiagnosed. The authors presented a case of vestibular schwannoma in a 36-year-old woman. The clinical manifestations were recurrent vertigo, hearing loss of the left ear, and tinnitus. The pure tone audiometry threshold of the left ear was 45dBHL with air conduction, and 33 dBHL with bone conduction. A CT scan of the temporal bone region didn't show any abnormal finding. A MRI scan of the head showed nodule abnormal signal in the internal of left vestibular and the narrow of perilymphaticum gap in T2W1 + T2Flair. The initial diagnosis was Meniere's disease. And the post-operation pathologic diagnosis was vestibular schwannoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Radiologic Findings after Transpromontorial Approach: Clinical and Pathophysiological Considerations.
Otol Neurotol
February 2025
Department of Otolaryngology Head and Neck Surgery, University Hospital of Modena, Modena, Italy.
Objectives: Transpromontorial approaches require obliteration of the surgical cavity and the eustachian tube, along with cul-de-sac external auditory canal closure, without obliteration of the mastoid air cells. This study aims to evaluate the clinical and radiological implications of tympanic cavity obliteration when the mastoid air cell system is preserved.
Study Design: Retrospective observational study.
Microscale Proteomic Analysis of the Endolymphatic Sac in Menière's Disease Patients.
Otol Neurotol
February 2025
Department of Otolaryngology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Objective: Endolymphatic hydrops is the primary pathological feature of Menière's disease (MD). An imbalance between endolymphatic fluid production and absorption due to endolymphatic sac (ES) dysfunction may be the major cause of endolymphatic hydrops. This study aimed to identify and characterize global protein expression of the ES in MD patients using microscale proteomics for the first time.
View Article and Find Full Text PDFEffect of Simvastatin on Irradiated Primary Vestibular Schwannoma Cells.
Otol Neurotol
February 2025
Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida.
Hypothesis: Simvastatin enhances radiation cytotoxicity of primary vestibular schwannoma (VS) and NF2-mutant human Schwann (HS01) cells.
Background: Approximately 10% of VS progress after radiotherapy. Simvastatin is a lipid-lowering medication that promotes apoptosis, inhibits cell proliferation, and enhances radiation response in various cancers.
Gene therapy and genome-editing for schwannoma in NF2-related schwannomatosis: current understanding and future directions.
J Neurooncol
March 2025
Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
NF2-related schwannomatosis (NF2-SWN) is a rare genetic disorder characterized by bilateral vestibular schwannomas. NF2-SWN represents a difficult management problem with most patients facing substantial morbidity and reduced life expectancy. Gene therapy involves replacing a faulty gene or adding a new gene in an attempt to cure disease or improve the patient's condition.
View Article and Find Full Text PDFNF2-related schwannomatosis: A view from within the inner ear.
Hear Res
February 2025
UCL Ear Institute, University College London, 332 Gray's Inn Road, London, WC1X 8EE, UK. Electronic address:
NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) is an autosomal dominant disorder associated with the growth of bilateral schwannomas on the cochleo-vestibular nerves and meningiomas. NF2-SWN is caused by pathogenic variations in the NF2, moesin-ezrin-radixin-like (MERLIN) tumour suppressor gene. The mostly benign tumours can cause progressive sensorineural hearing loss, tinnitus and balance dysfunction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!